Search alternatives:
mean decrease » a decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search)
mean decrease » a decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search)
-
161
-
162
-
163
Neuronal expression of A53T, E46K, G51D, and H50Q αSyn showed an early decline in locomotor function.
Published 2019“…Flies expressing either A53T, E46K, G51D, or H50Q αSyn showed a significant decrease in locomotor function compared with control flies, whereas flies expressing WT αSyn did not. …”
-
164
Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
165
Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
166
-
167
-
168
WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression.
Published 2024“…<b>C.</b> RT-qPCR of WT1, p<0.05(*), vFLIP(ns), LANA, p<0.0001(****), K8.1, p<0.0001(****), and BCL2 p<0.05(*) in the setting of WT1 knockdown in ISLK BAC-16 with WT1 siRNA in comparison to a control siRNA using two-sided, unpaired student’s t-tests. …”
-
169
-
170
-
171
-
172
-
173
-
174
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…(B) For each group, the median Ki-67 immunostained parathyroid sample closest to the group mean is shown. Each dot represents one sample. Scale bars measures 50μm.…”
-
175
-
176
Exposure to low CO<sub>2</sub> levels decreases ER cholesterol levels.
Published 2023“…<b>(F)</b> qPCR analysis for cholesterogenic genes from NIH3T3 cells exposed to cholesterol (50 μm) or 25-hydroxycholesterol (10 μm) under 5% or 1% CO<sub>2</sub> for 4 h (mean ± SE, <i>n</i> = 3 biological replicates per condition, ***<i>P</i> < 0.001, nonsignificant (ns), two-way ANOVA with Bonferroni’s multiple comparisons test). …”
-
177
Decreased ISCs and increased goblet cells after intestinal specific loss of MLL1.
Published 2021“…Tamoxifen was given by gavage for 6 days to mice with the genotype <i>Mll1</i><sup><i>FC/+; Vil-Cre-ERT2/+</i></sup> (n = 12) and <i>Mll1</i><sup><i>FC/FC; RC/+</i></sup> (n = 18). …”
-
178
-
179
-
180